EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease

Michael Mederer iD, Johanna Piater iD, Felix Keller iD, Barbara Enrich, Veronika Cibulkova iD, Valeria Wagner, Rebecca Giquel-Fernandes, Andreas Kronbichler iD, Herbert Tilg iD, Maria Effenberger

Life · 30.03.2026 · 16 (4) · 563

DOI: 10.3390/life16040563 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life, online erschienen am 30.03.2026. Verfasst von Michael Mederer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "AI in medicine" program from the Land Tirol, Austrian Society of Gastroenterology and Hepatology (Wissenschaftsfond), “AI in medicine” from the Land Tirol.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) remains a leading cause of mortality in patients with advanced chronic liver disease (ACLD), particularly in those with decompensated cirrhosis, where traditional biomarkers such as alpha-fetoprotein (AFP) often fail to reliably detect malignancy. Interleukin-37 (IL-37), an anti-inflammatory cytokine with reported tumour-suppressive properties, has emerged as a candidate biomarker in hepatocarcinogenesis. This prospective study investigated serum IL-37 concentrations in 221 patients with ACLD (54 with HCC and 167 without HCC). IL-37 was measured at the time of clinical assessment, and routine laboratory parameters, disease severity scores (MELD, Child–Pugh), and tumour staging (BCLC, LI-RADS) were recorded. IL-37 levels were not significantly different in patients with compensated ACLD (cACLD) with or without HCC. In contrast, in decompensated ACLD (dACLD), IL-37 concentrations were significantly lower in patients with HCC, particularly in those with advanced hepatic dysfunction. Stratified analyses revealed an inverse relationship between IL-37 and AFP in cACLD, whereas in dACLD, IL-37 appeared more informative, as AFP levels were affected by systemic inflammation. Patients with prevalent HCC exhibited numerically lower IL-37 compared with those who developed HCC during follow-up, suggesting that IL-37 decline may precede overt tumour manifestation. Kaplan–Meier survival analysis showed a trend toward improved overall survival in patients with higher IL-37 levels, although this did not reach statistical significance. These findings highlight IL-37 as a promising biomarker candidate that might reflect immune regulation and tumour biology in ACLD. In particular, IL-37 may complement AFP for HCC detection in decompensated cirrhosis, where conventional biomarkers often fail. Future studies with larger, longitudinal cohorts are warranted to validate IL-37 as a predictive and prognostic marker in high-risk populations.

Schlagwörter

Stichwörter der Autor:innen

ACLDHCCIL-37alpha-fetoproteinbiomarkercACLDcirrhosisdACLD

Autor:innen und Institutionen

  • Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University of Innsbruck, 6020 Innsbruck, Austria.
  • Department of Internal Medicine IV, Nephrology & Hypertension, Medical University of Innsbruck, 6020 Innsbruck, Austria.

ORCID-Profile: Michael Mederer, Johanna Piater, Felix Keller, Veronika Cibulkova, Andreas Kronbichler, Herbert Tilg

Förderung

  • "AI in medicine" program from the Land Tirol
  • Austrian Society of Gastroenterology and Hepatology (Wissenschaftsfond)
  • “AI in medicine” from the Land Tirol

Zitieren

APA

Mederer, M., Piater, J., Keller, F., Enrich, B., Cibulkova, V., Wagner, V., Giquel-Fernandes, R., Kronbichler, A., Tilg, H., & Effenberger, M. (2026). Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease. Life, 16(4), 563. https://doi.org/10.3390/life16040563

Vancouver

Mederer M, Piater J, Keller F, Enrich B, Cibulkova V, Wagner V, et al. Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease. Life. 2026;16(4):563. doi:10.3390/life16040563

BibTeX
@article{Mederer2026,
  author = {Mederer, Michael and Piater, Johanna and Keller, Felix and Enrich, Barbara and Cibulkova, Veronika and Wagner, Valeria and Giquel-Fernandes, Rebecca and Kronbichler, Andreas and Tilg, Herbert and Effenberger, Maria},
  title = {Circulating Interleukin-37 as a Biomarker Candidate for Hepatocellular Carcinoma in Decompensated Advanced Chronic Liver Disease},
  journal = {Life},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {563},
  doi = {10.3390/life16040563}
}
Kostenlos starten →